In The News Posted June 21, 2019 Share Posted June 21, 2019 SEATTLE, Wash. and VANCOUVER, British Columbia, June 21, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced that an abstract featuring data from the Phase 2b ORCA-1 trial has been accepted ... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.